CTNNB1 and cancer: However, PORCNi treatment did not reduce proliferation in intestinal crypts harbouring homozygous Apc mutations [64], suggesting that cancers that harbour mutations in the destruction complex or activating mutations in CTNNB1 are likely to be insensitive to PORCNi treatment since these mutations activate the Wnt pathway downstream of the Wnt receptor complexes.